Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet
Janssen Pharmaceutical Companies of Johnson & Johnson | April 11, 2019
MIAMI, April 11, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson unveiled new 48-week data for SYMTUZA® (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg D/C/F/TAF) showing that a high proportion of HIV patients achieved an undetectable viral load through 48 weeks after rapidly starting SYMTUZA®. A secondary endpoint of the study also showed that 97% of patients reported they were satisfied with their treatment.1 The results from the DIAMOND study – the first prospective Phase 3 trial studying the rapid initiation of a single-tablet regimen (STR) – were presented at the 13th Annual American Conference for the Treatment of HIV (ACTHIV 2019) in Miami, Florida. The DIAMOND study evaluated the once-daily STR SYMTUZA® for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult patients who were enrolled within 14 days of receiving an HIV diagnosis and then started on SYMTUZA® before laboratory or baseline resistance test results were available.1 SYMTUZA® is approved by the U.S. Food & Drug Administration (FDA) for the treatment of HIV-1 infection in treatment-naïve and certain virologically suppressed adults.